Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Reformulated Ibuprofen 2% and 4% Suspensions vs Nurofen in Healthy Adults
NCT07036861Phase 1Completed
- Sponsor
- Menarini Group
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen in pain, fever and inflammation (3 arms), sponsored by Menarini Group. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and 1 more. Started Nov 2023; status: completed.
02
Drugs
ibuprofen
03
Conditions
painfeverinflammation
Beyond the preview
Go deeper on NCT07036861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036861.